Johnson & Johnson
JOHNSON & JOHNSON (Form: 8-K, Received: 10/02/2017 16:53:59)







UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  October 2, 2017


JJLOGOFORWEBFILINGA05A02A02.JPG

(Exact name of registrant as specified in its charter)

New Jersey
I-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)


One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:  732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o      

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o  










Item 8.01 Other Events.
On October 2, 2017, the company announced the completion of the divestiture of its Codman Neurosurgery business to Integra LifeSciences Holding Corporation for an approximate value of $1.045 billion, subject to customary adjustments.
The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of approximately $371.5 million in 2016.
The related press release dated October 2, 2017 is attached as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.     
(d)     Exhibits.    

Exhibit No.      Description
99.1 Johnson & Johnson press release dated October 2, 2017.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
Johnson & Johnson
 
 
 
 (Registrant)
 
Date: October 2, 2017
By:
/s/ Tina S. French
 
 
 
Tina S. French
 
 
 
Assistant Secretary
 
 
 
 
 

 






Exhibit 99.1


JJLOGOFORWEBFILINGA05A02A02.JPG
FOR IMMEDIATE RELEASE

 
Media Contact:
Kassy McGourty
908-377-5873
 
 
 
 
 
 
 
Investor Relations Contact:
Jason Valmore
732-524-3709
 


Johnson & Johnson Announces Completion of Codman Neurosurgery Divestiture to
Integra LifeSciences Holding Corporation
NEW BRUNSWICK, N.J., October 2, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the divestiture of its Codman Neurosurgery business to Integra LifeSciences Holding Corporation for an approximate value of $1.045 billion, subject to customary adjustments.
The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of approximately $371.5 million in 2016.
Johnson & Johnson remains dedicated to ischemic and hemorrhagic stroke treatment through its newly launched Johnson & Johnson Medical Devices Companies* platform, CERENOVUS**, with a portfolio that includes aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke. The CERENOVUS product portfolio has been expanded through the recent acquisitions of Pulsar Vascular Inc., with a specialty in the endovascular treatment of wide-neck bifurcated aneurysms, and Neuravi Limited, offering extensive expertise and knowledge in acute ischemic stroke with its EmboTrap ® Revascularization Platform.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.
*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.
**Cerenovus is part of the Johnson & Johnson Medical Devices Companies.